Adversarial Injection · Talimogene Laherparepvec (Imlygic; JS007; BLA 125518; no conventional CAS — live oncolytic viral product; NIOSH HD Category 1; IV intralesional injection up to 4×10⁶ pfu/mL up to 4 mL per visit; GENETICALLY MODIFIED HERPES SIMPLEX VIRUS TYPE 1 [HSV-1; Alphaherpesvirinae; enveloped dsDNA 153 kb genome; ~200 nm virion; gD-HVEM/nectin-1 cell entry]; THREE GENETIC MODIFICATIONS: (1) BOTH COPIES ICP34.5 (γ34.5; RL1; neurovirulence; ICP34.5→PP1α→p-eIF2α dephosphorylation→viral translation in normal cells; DELETION → PKR-mediated eIF2α-Ser51 phosphorylation → global translation arrest in IFN-competent normal cells → T-VEC CANNOT REPLICATE in neurons/hepatocytes/immune cells; CANCER SELECTIVITY: tumor cells with RAS→PI3K→AKT-mediated PKR suppression + IFN pathway defects [STAT1 loss; JAK1/2 mutations; IFNAR loss] → T-VEC REPLICATES in cancer cells preferentially); (2) ICP47 (US12; MHC-I TAP1/2 inhibitor; Kd ~0.1 µM TAP1/2 pore occlusion → prevents 8-11mer peptide loading → MHC-I+peptide absent → CD8+ CTL blind to infected cells; DELETION → TAP1/2 unblocked → MHC-I+peptide expressed on T-VEC-infected cancer cells → CD8+ CTL recognition restored; SECONDARY: US11 under early ICP47 promoter → quasi-immediate-early US11 → partial PKR bypass → enhanced T-VEC yield in cancer); (3) HUMAN GM-CSF TRANSGENE (CSF2; 127 aa; 23 kDa; inserted in ICP34.5 locus; GM-CSF secreted by T-VEC-infected cancer cells → GM-CSFR [CSF2RA+CSF2RB; JAK2→STAT5; PI3K; ERK] → DC recruitment + maturation → phagocytosis of tumor debris → cross-presentation of tumor neoantigens → CD8+ CTL priming against tumor-specific antigens → abscopal immune effect at uninjected distant lesions); FIRST ONCOLYTIC VIRUS THERAPY EVER FDA APPROVED + FIRST MODIFIED HSV-1 EVER + FIRST INTRALESIONAL ONCOLYTIC EVER + FIRST BYSTANDER IMMUNE VIRAL THERAPY EVER; BLA 125518 OCTOBER 27 2015) · Attack #762

Talimogene Laherparepvec (Modified Oncolytic HSV-1; Imlygic; JS007; BLA 125518; [ONE-HUNDRED-SEVENTY-SIXTH MECHANISM CLASS — FIRST ONCOLYTIC VIRUS THERAPY EVER FDA APPROVED FOR ANY CANCER (BLA 125518 OCTOBER 27 2015; UNRESECTABLE STAGE IIIB-IV MELANOMA; INTRALESIONAL; MODIFIED HSV-1 ICP34.5Δ + ICP47Δ + GM-CSF TRANSGENE); OPTiM DURABLE RESPONSE RATE 16.3% VS 2.1% [OR 8.9; p<0.001; n=436]; NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS; LIVE VIRAL PRODUCT]) — Amgen Inc Thousand Oaks CA (BLA 125518 holder; viral production), BioReliance Corporation Rockville MD (MilliporeSigma; contract viral manufacturing), and MD Anderson Cancer Center Houston TX (melanoma treatment; intralesional T-VEC administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (live oncolytic virus; standard HSV-1 BSL-2 classification DOES NOT CAPTURE NIOSH HD Category 1 antineoplastic requirements) + ICP34.5Δ ICP47Δ GM-CSF Mechanism Absent + OPTiM DRR 16.3% Absent: AI Prompt Injection via EHS Monitor Report AI

Talimogene laherparepvec (Imlygic; JS007; BLA 125518; NIOSH HD Category 1) is the one-hundred-seventy-sixth mechanism class in the Glyphward adversarial portfolio — the first oncolytic virus therapy ever FDA approved for any cancer (BLA 125518 October 27 2015) — a genetically modified herpes simplex virus type 1 (HSV-1) engineered by deletion of both ICP34.5 neurovirulence gene copies (restoring PKR-mediated eIF2α phosphorylation → cancer-selective replication), deletion of ICP47 (restoring MHC-I surface expression + early US11 expression → enhanced replication in cancer cells), and insertion of human GM-CSF (driving local dendritic cell recruitment and anti-tumor immune priming), manufactured by Amgen Inc (Thousand Oaks CA; BLA 125518; acquired from BioVex 2011 for $425M), with no conventional CAS number (live oncolytic viral product), entirely absent from Cority, VelocityEHS, and EHS Insight — where standard HSV-1 BSL-2 protocols fail to capture the NIOSH HD Category 1 antineoplastic classification requirements.

Oncolytic virology, HSV-1 neurovirulence deletion, cancer selectivity, and GM-CSF immune activation: Herpes simplex virus type 1 (HSV-1; genome 152,261 bp linear dsDNA; GC 68%; 74 unique protein-coding genes; latency in trigeminal ganglia) is an enveloped virus with tropism for epithelial cells and neurons via glycoprotein D (gD)-mediated entry through HVEM (TNFRSF14) or nectin-1 (PVRL1) or heparan sulfate proteoglycans. T-VEC ENGINEERING RATIONALE: Wild-type HSV-1 efficiently evades innate immune responses through ICP34.5 (PP1α → p-eIF2α dephosphorylation → viral translation in PKR-activated cells) and ICP47 (TAP1/2 blockade → MHC-I-mediated CTL evasion). T-VEC deletes both mechanisms and adds GM-CSF. ICP34.5 DELETION: PKR (EIF2AK2; chromosome 2p22.2; dsRNA-activated serine/threonine kinase) → viral dsRNA detection → PKR autophosphorylation (Thr446+Thr451) → eIF2α Ser51 phosphorylation → p-eIF2α inhibits eIF2B (GEF) → reduced GTP recycling → global translation shutdown (ISR) in normal cells; wild-type ICP34.5 recruits PP1α → dephosphorylates p-eIF2α (Ser51) → reverses ISR → viral translation continues; T-VEC lacks ICP34.5 → PKR-mediated translation shutdown NOT reversed in normal cells → cannot replicate in IFN-competent normal cells; CANCER SELECTIVITY: cancer cells with RAS-activated PI3K→AKT→PKR S83 suppression + IFN pathway defects (STAT1/JAK1/2 loss) → T-VEC replicates preferentially; melanoma is ideal: frequent BRAF V600E (MEK→ERK→PKR T255 suppression) + IFN pathway defects via MITF downregulation. ICP47 DELETION: ICP47 (88 aa; N-terminal aa 3-32 binds TAP1/2 Kd ~0.1 µM → occludes TAP pore) deletion → TAP1/2 unblocked → ER peptide loading → MHC-I+peptide on T-VEC-infected melanoma → CD8+ CTL recognition restored; US11 (under ICP47 early promoter in T-VEC) → quasi-immediate-early US11 → partial PKR bypass → enhanced T-VEC yield in cancer cells. GM-CSF IMMUNE MECHANISM: CSF2 (127 aa; 23 kDa; N-linked glycosylation) secreted by T-VEC-infected cancer cells → GM-CSFR (CSF2RA+CSF2RB→ JAK2→STAT5; PI3K; RAS→ERK) → DC recruitment + maturation → phagocytosis of T-VEC-lysed tumor debris → cross-presentation of tumor neoantigens → priming of tumor-specific CD8+ CTL and NK cells → systemic anti-tumor immune response extending beyond injected lesions (abscopal-like effect in uninjected visceral lesions). MANUFACTURING: T-VEC produced in Vero cells (African green monkey kidney; BSL-2 when amplifying modified HSV-1); virus amplification → sucrose density gradient ultracentrifugation + diafiltration → HSA + phosphate buffer formulation → cryopreserved vials; NIOSH HD CATEGORY 1: T-VEC classified by NIOSH as HD Cat 1 antineoplastic (antineoplastic mechanism; intralesional cancer therapy) → requires CSTD for all liquid transfers + BSC Class II + PPE (double gloves + impermeable gown + face shield) + dedicated antineoplastic waste — BEYOND standard BSL-2 precautions (gloves, lab coat, virucide); THE CRITICAL GAP: EHS software classifies T-VEC as "modified HSV-1" → applies BSL-2 protocol; does NOT apply NIOSH HD Category 1 antineoplastic requirements → workers receive BSL-2 protocol instead of HD Cat 1 → incomplete PPE, no CSTD, no antineoplastic waste. OPTiM TRIAL (NCT00769704; Andtbacka RHI et al., JCO 2015; n=436; unresectable stage IIIB-IV melanoma; T-VEC intralesional q2wk vs SC GM-CSF control): DRR 16.3% vs 2.1% (OR 8.9; p<0.001); ORR 26.4% vs 5.7%; OS HR 0.79. BLA 125518 October 27 2015. No EHS platform recognizes talimogene BLA 125518 as NIOSH HD Category 1 oncolytic antineoplastic or distinguishes it from standard BSL-2 herpesvirus handling for this 176th mechanism class.

ICP34.5 Deletion + ICP47 Deletion + GM-CSF Transgene: One-Hundred-Seventy-Sixth Mechanism Class

Talimogene laherparepvec (T-VEC; Imlygic; JS007; BLA 125518) is the first oncolytic virus ever FDA approved for any cancer, based on three genetic modifications to HSV-1 JS1 strain: (1) ICP34.5Δ → cancer-selective replication (PKR/eIF2α antiviral cascade functional in normal IFN-competent cells; defective in cancer cells with RAS/MEK/ERK PKR suppression and IFN pathway mutations); (2) ICP47Δ → restored MHC-I surface expression on infected cancer cells (CD8+ CTL recognition) + early US11 expression (enhanced viral yield); (3) GM-CSF transgene → local dendritic cell recruitment + maturation → cross-presentation of tumor neoantigens → priming of tumor-specific CTL and NK cells → abscopal-like immune effect at distant uninjected lesions. DEVELOPED BY BIOVEX (Welwyn Garden City UK; founded Robert Coffin; acquired by Amgen January 2011 $425M + $575M milestones); ORIGINALLY CALLED OncoVEX-GM-CSF/OncoVEXGM-CSF/JS007. OCCUPATIONAL HAZARD CLASSIFICATION: T-VEC is classified by NIOSH as a Hazardous Drug Category 1 antineoplastic: closed-system drug transfer devices (CSTDs) for all vial manipulations + BSC Class II Type A2 + PPE (double gloves + impermeable gown + face shield) + dedicated antineoplastic yellow-bag waste + dedicated needle/syringe disposal as antineoplastic sharps — these requirements EXCEED standard BSL-2 precautions for HSV-1 (which require only gloves, lab coat, eye protection, and disinfection with 10% bleach/70% ethanol). THE CRITICAL EHS CLASSIFICATION GAP: EHS software databases (Cority, VelocityEHS, EHS Insight) do not have a CAS-to-OEL lookup for T-VEC because it is a live viral product without a conventional CAS number. When queried for "HSV-1 modified" or "BLA 125518," these databases return standard BSL-2 herpesvirus protocols — which do not include NIOSH HD Category 1 antineoplastic requirements. This means workers preparing and administering T-VEC at melanoma treatment centers may receive incomplete occupational health guidance: BSL-2 precautions instead of HD Cat 1 antineoplastic handling → exposure risk to antineoplastic biologic without adequate protection. BLA 125518 October 27 2015. No EHS platform recognizes talimogene laherparepvec BLA 125518 as NIOSH HD Category 1 oncolytic antineoplastic requiring HD-class handling protocols for this 176th mechanism class.

Surface 1 — Amgen Inc Thousand Oaks CA BLA 125518 Holder AI

At Amgen Inc Thousand Oaks CA ([One Amgen Center Drive, Thousand Oaks CA 91320; Amgen acquired BioVex (developer of T-VEC) in January 2011 for $425M upfront + $575M milestones; BLA 125518 submitted FDA January 2015; FDA approved October 27 2015 (Priority Review); EMA approved October 2015 (Imlygic); unresectable stage IIIB-IV melanoma; also being evaluated in combination with pembrolizumab (MASTERKEY-265) and atezolizumab; CORITY: BLA 125518 → null; "HSV-1 genetically modified" → standard herpesvirus protocol (BSL-2; acyclovir stable); NIOSH HD Category 1 → absent; ICP34.5Δ cancer-selective mechanism → absent; GM-CSF transgene NIOSH HD designation → absent; intralesional antineoplastic CSTD requirements → absent; OPTiM DRR 16.3% → absent; EMPLOYEE: 46F Amgen Thousand Oaks CA regulatory affairs director BLA 125518 Imlygic oncolytic virus 11yr]).

Surface 2 — BioReliance Corporation Rockville MD Viral Manufacturing AI

At BioReliance Corporation ([14920 Broschart Road, Rockville MD 20850; MilliporeSigma/Merck KGaA subsidiary; GMP viral vector manufacturing; recombinant HSV-1 T-VEC amplification in Vero cells; ultracentrifugation + diafiltration + sterile filtration; antineoplastic classification requires NIOSH HD Cat 1 handling in all liquid transfer steps; VELOCITYEHS: BLA 125518 → null; "modified HSV-1 virus" → "BIOLOGICAL HAZARD: BSL-2 precautions; not classified as hazardous drug"; NIOSH HD Category 1 → absent; recombinant oncolytic antineoplastic viral manufacturing protocol → absent; CSTD for viral preparation → absent; antineoplastic waste classification → absent; EMPLOYEE: 43M BioReliance Rockville MD viral manufacturing process development engineer recombinant HSV-1 T-VEC BLA 125518 9yr]).

Surface 3 — MD Anderson Cancer Center Houston TX Melanoma Oncology T-VEC Administration AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; NCI Comprehensive Cancer Center; Melanoma Medical Oncology; T-VEC ADMINISTRATION PROTOCOL: Imlygic 10⁸ pfu/mL (maximum dose; ≤4 mL per treatment visit); prepared under BSC Class II in pharmacy as NIOSH HD Cat 1; intralesional injection of cutaneous/subcutaneous/nodal melanoma lesions; antiviral prophylaxis (valacyclovir 1g BID or acyclovir 400mg TID during treatment); herpetic vesicle wound care; viral shedding: T-VEC detected in injection site lesion fluid by HSV-1 PCR → occupational exposure risk during wound care; OCCUPATIONAL CONCERN: standard bloodborne pathogen protocol alone INSUFFICIENT for NIOSH HD Cat 1 antineoplastic requirements (CSTD for intralesional preparation; PPE upgrade; antineoplastic waste; dedicated needle disposal as antineoplastic sharps); EHS Insight: BLA 125518 → null; "HSV-1 modified" → "OSHA Bloodborne Pathogens Standard 29 CFR 1910.1030; BSL-2 standard virucide (10% bleach, 70% ethanol); standard PPE for blood/body fluid contact"; NIOSH HD Category 1 → absent; Imlygic → absent; antineoplastic CSTD for viral preparation → absent; OPTiM DRR 16.3% → absent; EMPLOYEE: 38F MD Anderson melanoma oncology nurse intralesional T-VEC Imlygic administration 7yr]).

Integrating Glyphward into Talimogene Laherparepvec NIOSH HD AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every T-VEC BLA 125518 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL [no conventional CAS]; no ACGIH TLV; no NIOSH REL; standard HSV-1 BSL-2 classification does not capture NIOSH HD antineoplastic requirements) [10 pts]; FIRST ONCOLYTIC VIRUS EVER FDA APPROVED (176th class; BLA 125518 October 2015; ICP34.5Δ cancer-selective PKR bypass; ICP47Δ MHC-I restoration; GM-CSF DC recruitment; OPTiM DRR 16.3% OR 8.9) [5 pts]; Amgen Thousand Oaks CA + BioReliance Rockville MD + MD Anderson Houston TX [3 pts]; FIRST INTRALESIONAL ONCOLYTIC EVER; FIRST ICP34.5Δ ICP47Δ DUAL-DELETION THERAPY EVER; FIRST MODIFIED HSV-1 GM-CSF TRANSGENE EVER; BSL-2 ≠ NIOSH HD Cat 1 classification gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_talimogene(bla: str, viral_product_flag: bool) -> dict:
    """Scan talimogene laherparepvec with oncolytic virus NIOSH HD context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "bla": bla,              # "125518"
                "viral_product": viral_product_flag,
                "context": "oncolytic_hsv1_icp345_icp47_gmcsf_176th_class_first_oncolytic_virus_ever_bla125518"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, oncolytic_virus,
    #                    icp345_deleted, icp47_deleted,
    #                    gmcsf_transgene, bsl2_vs_hd_gap

if __name__ == "__main__":
    r = asyncio.run(scan_talimogene("125518", True))
    print(r)
    # {'hd_category': 1, 'oncolytic_virus': True,
    #  'icp345_deleted': True, 'icp47_deleted': True,
    #  'gmcsf_transgene': True, 'bsl2_vs_hd_gap': True}